South America Pharmaceutical Plastic Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The South America pharmaceutical plastic packaging market size was USD 1.86 billion in 2025 and is forecast to reach USD 2.91 billion by 2031 at a CAGR of 7.68% during 2026-2031. This report is segmented by Material (PP, PET, HDPE, LDPE, and More), Product Type (Bottles and Solid Containers, Vials and Ampoules, and More), Format (Rigid, and Flexible), Route of Drug Delivery (Oral, Parenteral / Injectable, and More), End-User (Pharma Manufacturers, Hospitals and Clinics, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

South America Pharmaceutical Plastic Packaging Market Trends and Insights

Expansion of Generic-Drug Manufacturing

Brazil's generic drug sector is the largest single source of packaging demand in the region. ANVISA indicated that a large share of generic drugs sold in Brazil were produced domestically in recent years. The continued localization of production supports recurring demand for bottles, blister packs, and closures. Argentina's Ministry of Health reported that generic medications accounted for a substantial share of its pharmaceutical market. Larger domestic manufacturers are narrowing their polymer grade panels, which reduces the requalification burden under ANVISA requirements. This standardization favors packaging suppliers with approved material specifications and high-throughput PP lines. Generic production also concentrates purchasing decisions among major drug manufacturers. That concentration can make volume contracts more predictable for converters that already meet the required standards. PP bottles, blister packs, and polypropylene closures remain aligned with the needs of high-volume tablet and solid-dose production. Suppliers must also maintain reliable quality documentation because established grades are difficult to replace once a drug product is qualified. The South America pharmaceutical plastic packaging market benefits from this base of routine demand even when specialized formats receive more attention. Local manufacturing capacity, therefore, supports volume continuity across several national procurement systems.

Growth in Biologics and Injectable Therapies

Biologics are shifting demand toward primary containers with stricter performance requirements. COP and COC received formal European Pharmacopeia recognition in 2025 through new chapters from the European Directorate for the Quality of Medicines. The recognition helps reduce documentation barriers for biosimilar developers using these materials. COP and COC provide low extractables, low protein adsorption, optical clarity, and dimensional precision. These attributes are important for biologics and injectable fill-finish operations. The South America pharmaceutical plastic packaging market consequently has a higher need for qualified cartridges and related primary components. West Pharmaceutical Services raised its organic revenue outlook, while High-Value Product component revenue increased significantly, indicating sustained global investment in injectable containment systems. Locally produced GLP-1 pen devices have also created demand for cartridge packaging at Brazilian fill-finish sites. Existing regional supply has limited capacity for COP and COC cartridges manufactured to the required tolerances, creating import dependency while qualification programs develop. Suppliers that combine material expertise with validated manufacturing can address this requirement.

Availability of Alternative Packaging Materials

Glass remains an established alternative for injectable pharmaceutical products. Borosilicate Type I vials, ampoules, and prefillable glass syringes have established regulatory acceptance. SCHOTT Pharma reported continued revenue growth, reflecting sustained demand for glass pharmaceutical packaging. Glass-to-polymer conversion requires requalification studies, stability data, and regulatory submissions. These requirements delay material changes for many mid-tier drug manufacturers. Aluminum foil laminates and non-plastic blister materials also compete in selected solid-dose applications. The cost and duration of qualification can limit polymer conversion in tender-led public programs. Price pressure makes it harder to justify a switch when established glass formats already meet the drug product specification. High-value biologics can support polymer adoption where break resistance, weight, or device integration are important. However, glass remains relevant in vials, ampoules, and syringe applications. The South America pharmaceutical plastic packaging market must therefore compete on a clear technical or operating benefit. Material choice will continue to depend on product stability, regulation, and the cost of changing validated packaging systems.

Other drivers and restraints analyzed in the detailed report include:

• Serialization and Traceability Upgrades
• Shift Toward Lightweight and Recyclable Packaging
• Volatility in Polymer and Additive Costs

Segment Analysis

Polypropylene held 29.23% of the South America pharmaceutical plastic packaging market share in 2025. Its position reflects compatibility with solid oral dosage forms and an economical fit for high-volume generic production. PP bottles, closures, and strip packs support Brazil's domestic generic drug manufacturing base. Regulatory acceptance from ANVISA and ANMAT also supports continued use of these established materials. PET provides chemical resistance and optical clarity for liquid oral formulations and selected parenteral containers. HDPE is used for moisture-sensitive products because its barrier performance exceeds standard PP grades in those applications. LDPE remains relevant for eye drops, nasal sprays, squeeze containers, and unit-dose formats. Its lower oxygen barrier limits its use compared with HDPE and PP in more demanding applications.

COP and COC are projected to expand at an 8.11% CAGR through 2031, the highest rate among material categories. Their low extractables profile and glass-like clarity support biologics and biosimilar fill-finish requirements. Their dimensional precision also fits cartridges and other injection-related components. EDQM's 2025 pharmacopoeial chapters make submissions easier for developers using COP and COC. Bio-based and recycled plastics are still at an early adoption stage because qualified pharmaceutical-grade recyclate is not available in sufficient regional volumes. Supply arrangements with qualified overseas resin producers can give converters a compliance advantage as sustainability requirements tighten. Material selection in the South America pharmaceutical plastic packaging industry is consequently separating between broad-volume generic needs and more demanding injectable applications.

Bottles and solid containers accounted for 29.44% of the South America pharmaceutical plastic packaging market size in 2025. This share reflects the large volume of oral tablets, capsules, and related generic medicines made in Brazil and Argentina. High-throughput bottling lines are designed around public procurement volumes and established dispensing practices. Blister packs and strip packs also have a substantial role in over-the-counter and hospital-dispensed solid doses. PVC-PVDC and aluminum-plastic constructions remain common in these formats. Closures, caps, and lids maintain demand because every primary container requires an engineered closing component. Vials and ampoules serve parenteral medicines in both glass and plastic constructions. IV bags and flexible bags remain important for institutional infusion therapy and single-use contamination control.

Pre-fillable syringes and cartridges are projected to expand at an 8.23% CAGR through 2031. Demand comes from self-administration for diabetes, obesity, autoimmune conditions, and oncology. SCHOTT Pharma introduced a ready-to-use COC polymer cartridge for biologics, biosimilars, and emergency drugs in 2025. The product reflects the wider move toward ready-to-use delivery systems at fill-finish operations. Pouches, stick packs, and sachets address pediatric, geriatric, and home-care needs where unit dosing is important. ANVISA Good Manufacturing Practice requirements and ISO 15223-related labeling needs also shape product qualification. The South America pharmaceutical plastic packaging market has room for suppliers that can support both established oral formats and higher-specification injectable products.

Complete Report Scope:

• By Raw Material
  • Polypropylene (PP)
  • Polyethylene Terephthalate (PET)
  • High-Density Polyethylene (HDPE)
  • Low-Density Polyethylene (LDPE)
  • Cyclic Olefin Polymer / Copolymer (COP/COC)
  • Bio-Based and Recycled Plastics
• By Product Type
  • Bottles and Solid Containers
  • Vials and Ampoules
  • Pre-Fillable Syringes and Cartridges
  • Blister Packs and Strip Packs
  • Pouches / Stick Packs / Sachets
  • Closures, Caps and Lids
  • IV Bags and Flexible Bags
• By Packaging Format
  • Rigid
  • Flexible
• By Route of Drug Delivery
  • Oral
  • Parenteral / Injectable
  • Ophthalmic / Nasal
  • Topical / Transdermal
• By End-User
  • Pharma Manufacturers
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Hospitals and Clinics
  • Home-Care Settings
• By Geography
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Rest of South America

List of Companies Covered in this Report:

• Amcor plc
• Gerresheimer AG
• ALPLA Werke Alwin Lehner GmbH & Co KG
• Klockner Pentaplast Group
• AptarGroup, Inc.
• Silgan Holdings Inc.
• Greiner Packaging International GmbH
• West Pharmaceutical Services, Inc.
• Becton, Dickinson and Company
• Schott Pharma AG & Co. KGaA
• Constantia Flexibles Group GmbH
• Tekni-Plex, Inc.
• Pretium Packaging, L.L.C.
• Drug Plastics and Glass Company, Inc.
• Plastipak Holdings, Inc.
• Comar, LLC
• Nolato AB
• Videplast Industria de Embalagens Ltda
• Plastimax SA
• Inden Pharma
• LOG Plastic Products
• Eurofarma Embalagens
• Frapak Packaging B.V.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support